NASDAQ:SCPH

scPharmaceuticals - SCPH Stock Forecast, Price & News

$8.76

+0.23 (+2.70%)

(As of 03/27/2023 04:00 PM ET)

Add

Compare

Today's Range: $8.36
▼
$9.18
50-Day Range: $5.59
▼
$9.47
52-Week Range: $3.68
▼
$10.38

Volume: 337,091 shs
Average Volume: 546,227 shs
Market Capitalization: $240.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Institutional Ownership

scPharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 98.5% Upside
$18.00 Price Target
Short Interest: Bearish
17.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.90
Upright™ Environmental Score
News Sentiment: 0.29
Based on 16 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.58) to ($1.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

398th out of 995 stocks

Pharmaceutical Preparations Industry

181st out of 482 stocks

3.5

Analyst's Opinion

Consensus Rating
scPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, scPharmaceuticals has a forecasted upside of 98.5% from its current price of $9.07.
Amount of Analyst Coverage
scPharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
17.45% of the float of scPharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
scPharmaceuticals has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in scPharmaceuticals has recently increased by 3.83%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
scPharmaceuticals does not currently pay a dividend.
Dividend Growth
scPharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
scPharmaceuticals has received a 72.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.
Environmental Sustainability
The Environmental Impact score for scPharmaceuticals is -0.90.

1.8

News and Social Media Coverage

News Sentiment
scPharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 18 people have searched for SCPH on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.70% of the stock of scPharmaceuticals is held by insiders.
Percentage Held by Institutions
53.90% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.58) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of scPharmaceuticals is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of scPharmaceuticals is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
scPharmaceuticals has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About scPharmaceuticals (NASDAQ:SCPH) Stock

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Stock News Headlines

March 27, 2023 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Call Transcript

March 26, 2023 | americanbankingnews.com

Head to Head Comparison: scPharmaceuticals (NASDAQ:SCPH) vs. Calithera Biosciences (NASDAQ:CALA)

March 27, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

March 24, 2023 | finance.yahoo.com

When Will scPharmaceuticals Inc. (NASDAQ:SCPH) Turn A Profit?

March 24, 2023 | americanbankingnews.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Expected to Post FY2025 Earnings of $0.12 Per Share

March 24, 2023 | americanbankingnews.com

scPharmaceuticals (NASDAQ:SCPH) Receives "Buy" Rating from HC Wainwright

March 22, 2023 | finance.yahoo.com

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

March 15, 2023 | finance.yahoo.com

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

March 27, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

February 23, 2023 | finance.yahoo.com

scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference

February 21, 2023 | finance.yahoo.com

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

February 13, 2023 | marketwatch.com

2023-2027 Large Volume Wearable Injectors Market Size which includes Competitor Analysis and Market Dynamic Forecast | 98 Pages

February 6, 2023 | finance.yahoo.com

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 31, 2023 | finance.yahoo.com

scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

January 30, 2023 | finance.yahoo.com

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

January 10, 2023 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) stock most popular amongst private equity firms who own 41%, while individual investors hold 36%

December 20, 2022 | finance.yahoo.com

What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock

December 20, 2022 | finance.yahoo.com

Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?

December 19, 2022 | finance.yahoo.com

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

December 14, 2022 | finance.yahoo.com

scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event

November 29, 2022 | 247wallst.com

Orin Hirschman Discloses Position in SCPH / scPharmaceuticals

November 22, 2022 | finance.yahoo.com

scPharmaceuticals Announces Pricing of $50 Million Public Offering

November 22, 2022 | finance.yahoo.com

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

November 9, 2022 | finance.yahoo.com

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

November 2, 2022 | finance.yahoo.com

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

October 26, 2022 | finance.yahoo.com

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

October 20, 2022 | seekingalpha.com

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Company Calendar

Last Earnings: 3/22/2023
Today: 3/27/2023
Next Earnings (Estimated): 5/15/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SCPH
CUSIP: N/A
CIK: 1604950
Web: www.scpharma.com
Phone: (617) 517-0730
Fax: N/A
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +111.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.19%
Return on Assets: -49.01%

Debt

Debt-to-Equity Ratio: 0.51
Current Ratio: 16.63
Quick Ratio: 2.75

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.06 per share
Price / Book: 4.14

Miscellaneous

Outstanding Shares: 27,430,000
Free Float: 26,145,000
Market Cap: $233.98 million
Optionable: Not Optionable
Beta: 0.22

Key Executives

John H. Tucker
President, Chief Executive Officer & Director

Rachael Nokes
Treasurer, Chief Financial & Accounting Officer

John Mohr
Senior VP-Clinical Development & Medical Affairs

Mike Hassman
Senior Vice President-Technical Operations

Katherine Taudvin
Director-IR & Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SCPH Stock - Frequently Asked Questions

Should I buy or sell scPharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCPH shares.
View SCPH analyst ratings or view top-rated stocks.
What is scPharmaceuticals' stock price forecast for 2023?: 6 brokers have issued twelve-month price targets for scPharmaceuticals' stock. Their SCPH share price forecasts range from $13.00 to $25.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 111.0% from the stock's current price.
View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts.
How have SCPH shares performed in 2023?: scPharmaceuticals' stock was trading at $7.17 on January 1st, 2023. Since then, SCPH shares have increased by 19.0% and is now trading at $8.53.
View the best growth stocks for 2023 here.
When is scPharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our SCPH earnings forecast.
How were scPharmaceuticals' earnings last quarter?: scPharmaceuticals Inc. (NASDAQ:SCPH) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.12.
What ETFs hold scPharmaceuticals' stock?: ETFs with the largest weight of scPharmaceuticals (NASDAQ:SCPH) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).

What other stocks do shareholders of scPharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).
When did scPharmaceuticals IPO?: (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
What is scPharmaceuticals' stock symbol?: scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
Who are scPharmaceuticals' major shareholders?: scPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (9.30%), Armistice Capital LLC (7.83%), RA Capital Management L.P. (6.77%), Millennium Management LLC (3.01%), Dimensional Fund Advisors LP (0.78%) and Renaissance Technologies LLC (0.77%). Insiders that own company stock include 5Am Partners Iv, Llc, Andrew J Schwab, Jack A Khattar, John H Tucker and Orbimed Advisors Llc.
View institutional ownership trends.
How do I buy shares of scPharmaceuticals?: Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is scPharmaceuticals' stock price today?: One share of SCPH stock can currently be purchased for approximately $8.53.
How much money does scPharmaceuticals make?: scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $233.98 million. The company earns $-28,030,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.
How can I contact scPharmaceuticals?: scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com.

This page (NASDAQ:SCPH) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

scPharmaceuticals - SCPH Stock Forecast, Price & News

scPharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About scPharmaceuticals (NASDAQ:SCPH) Stock

SCPH Stock News Headlines

SCPH Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SCPH Stock - Frequently Asked Questions

Overall MarketRank^™